This Practice Note addresses frequently asked questions (FAQs) on social media communications relating to medicinal products in the UK. It focuses on the application of the Association of the British Pharmaceutical Industry (ABPI), Code of Practice for the Pharmaceutical Industry (ABPI Code) and the Prescription Medicines Code of Practice Authority (PMCPA) social media guidance to communications directed at healthcare professional (HCPs) and the public. The advertising and promotion of medicinal products is highly regulated because promotional activity can directly influence prescribing, purchasing, and treatment decisions, with potentially serious consequences for patient safety. The principal statutory framework is Part 14 of the Human Medicines Regulations 2012 (HMR 2012), SI 2012/1916. The Medicines and Healthcare products Regulatory Agency (MHRA) has also published the Blue Guide: Advertising and Promotion of Medicines in the UK (Blue Guide), which explains how those provisions are interpreted and enforced. The statutory framework is supplemented by industry self-regulatory codes of conduct, which are an integral part of the advertising practice compliance in the UK, with the greatest enforcement action seen at the